for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shandong Xinhua Pharmaceutical Company

0719.HK

Latest Trade

3.73HKD

Change

0.02(+0.54%)

Volume

418,000

Today's Range

3.66

 - 

3.79

52 Week Range

3.32

 - 

4.92

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
3.71
Open
3.66
Volume
418,000
3M AVG Volume
5.99
Today's High
3.79
Today's Low
3.66
52 Week High
4.92
52 Week Low
3.32
Shares Out (MIL)
621.86
Market Cap (MIL)
4,010.00
Forward P/E
--
Dividend (Yield %)
3.05

Next Event

Shandong Xinhua Pharmaceutical Co Ltd Annual Shareholders Meeting

Latest Developments

More

Shandong Xinhua Pharmaceutical Updates On Further Increase In Shareholding By Controlling Shareholder

Shandong Xinhua Pharmaceutical Posts 9-Mnth Operating Income Rmb4.40 Bln

Shandong Xinhua Pharmaceutical Co Announces Acquisition Of 33% Stake In A Co

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Shandong Xinhua Pharmaceutical Company

SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED is a China-based company principally engaged in the development, production and distribution of chemical bulk drugs, preparations and medical intermediates. The Company’s main products include metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, L-dopa, pipemidic acid tablets, compound liquorice tablets and nimodipine tablets. The Company distributes its products in domestic market and to overseas markets, including the Americas, Europe and others.

Industry

Biotechnology & Drugs

Contact Info

No.1 Lutai Avenue, High-tech Zone

+86.533.2166666

http://www.xhzy.com

Executive Leadership

Daiming Zhang

Chairman of the Board

Ning Hou

Chief Financial Officer

Deqing Du

Deputy General Manager

Tongqing He

Deputy General Manager

Chit Fun So

Financial Controller, Company Secretary

Key Stats

Price To Earnings (TTM)
7.08
Price To Sales (TTM)
0.64
Price To Book (MRQ)
0.72
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
60.28
LT Debt To Equity (MRQ)
23.95
Return on Investment (TTM)
8.86
Return on Equity (TTM)
5.40

Latest News

Latest News

BRIEF-Shandong Xinhua Pharmaceutical Scraps Asset Acquisition Plan, Share Trade To Resume

* SAYS IT SCRAPS ASSET ACQUISITION PLAN, SHARE TRADE TO RESUME ON FEB 14 Source text in Chinese: http://bit.ly/2o3zMif Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Shandong Xinhua Pharmaceutical Updates On Resumption Of Trading In A Shares

* CO APPLIED FOR RESUMPTION OF TRADING IN A SHARES ON SZSE WITH EFFECT FROM 14 FEB

BRIEF-Shandong Xinhua Pharmaceutical's Controlling Shareholder Warned By Regulator

* SAYS CONTROLLING SHAREHOLDER WARNED BY SECURITIES REGULATOR FOR VIOLATIONS OF INFORMATION DISCLOSURE Source text in Chinese: http://bit.ly/2C4R0k6 Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Shandong Xinhua Pharmaceutical Says H Share Trading To Continue

* APPLIED TO SHENZHEN STOCK EXCHANGE FOR SUSPENSION OF TRADING OF A SHARES ON SZSE WITH EFFECT FROM 25 JAN 2018

BRIEF-Shandong Xinhua Pharmaceutical's A-Share Trade To Halt Pending Asset Acquisition

* SAYS A-SHARE TRADE TO HALT FROM JAN 25 PENDING ANNOUNCEMENT RELATED TO ASSET ACQUISITION Source text in Chinese: http://bit.ly/2BohoFz Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Shandong Xinhua Pharmaceutical to pay A shares special div for FY 2017 on Jan. 26

* Says it will pay special cash dividend of 0.3 yuan(before tax)/10 shares for 2017 to shareholders of record on Jan. 25

BRIEF-Shandong Xinhua Pharmaceutical Sees Rise In FY Profit Attributable

* EXPECTED TO RECORD RISE IN NET PROFIT ATTRIBUTABLE TO SHAREHOLDERS DURING 2017

BRIEF-Shandong Xinhua Pharmaceutical Co announces special dividend

* Board resolved to recommend a special dividend of RMB0.3 for every 10 shares of co Source text for Eikon: Further company coverage:

BRIEF-Shandong Xinhua Pharmaceutical posts 9-month ‍net profit attributable of RMB173.7 mln

* 9-month net profit attributable to shareholders of co RMB173.7 million, up 94.74 percent

BRIEF-Shandong Xinhua Pharmaceutical ‍expects to record increase in net profit attributable for 9-months​

* Expected to record an increase in net profit attributable to shareholders for nine months Source text for Eikon: Further company coverage:

BRIEF-Shandong Xinhua Pharmaceutical posts HY net profit attributable of RMB106.8 mln

* Board proposes no interim dividends be declared for first half year of 2017

BRIEF- Shandong Xinhua Pharmaceutical sees H1 FY 2017 net profit up 100 pct to 150 pct

* Sees H1 FY 2017 net profit to increase by 100 percent to 150 percent, or to be 92 million yuan to 114 million yuan

BRIEF-Shandong Xinhua Pharmaceutical Co issues profit warning

* Expected to record an increase in net profit attributable to shareholders for period from 1 January 2017 to 30 June 2017

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up